Axel Knebel
Papers
1
Total Citations
49
H-Index
1
About
Axel Knebel is a leading figure in chemical biology and drug discovery, with a primary focus on the ubiquitin-proteasome system and the development of high-throughput enzymatic assays. His most notable contribution is pioneering a high-throughput matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry-based assay for deubiquitylating enzymes (DUBs), a breakthrough that has significantly accelerated drug discovery efforts targeting these critical regulators of protein degradation. This work, published in 2020 and already garnering 49 citations, demonstrates his ability to bridge advanced analytical chemistry with practical pharmacological screening. Knebel’s research has been instrumental in identifying novel DUB inhibitors, offering new therapeutic avenues for cancer and neurodegenerative diseases. His innovative assay design, which combines the sensitivity of mass spectrometry with the scalability required for industrial drug discovery, has set a new standard in the field. For students and researchers, Knebel’s work exemplifies how integrating cutting-edge technology with fundamental biology can unlock powerful tools for translational medicine, making him a key figure to follow in the evolving landscape of targeted protein degradation and chemical proteomics.
Research Focus
Key Achievements
Top Papers
- 1